Stockscreener 앱 받기
26.99
5.70%
-1.63
시간 외 거래:
28.05
1.06
+3.93%
전일 마감가:
$28.62
열려 있는:
$28.62
하루 거래량:
2.35M
Relative Volume:
1.69
시가총액:
$5.49B
수익:
-
순이익/손실:
$-464.20M
주가수익비율:
-10.06
EPS:
-2.6823
순현금흐름:
$-423.09M
1주 성능:
-4.56%
1개월 성능:
+12.55%
6개월 성능:
+22.79%
1년 성능:
+75.03%
1일 변동 폭
$26.00
$29.16
1주일 범위
$26.00
$30.09
52주 변동 폭
$13.36
$30.09
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.99 | 5.83B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wall Street analysts predict a 55.04% upside in Immunovant (IMVT): Here's what you should know - MSN
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CFO Tiago Girao Sells 25,760 Shares - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock By Investing.com - Investing.com India
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock - Investing.com
Immunovant (IMVT) CFO sells 25,760 shares to cover RSU tax - Stock Titan
Immunovant (IMVT) CTO sells 2,754 shares in tax sell-to-cover - Stock Titan
IMVT Price Today: Immunovant, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Immunovant (NASDAQ:IMVT) Sets New 12-Month HighHere's What Happened - MarketBeat
Immunovant (IMVT) Innovation Pipeline | Immunovant posts 16.3% EPS beat on narrower lossRating Downgrade - Xã Thanh Hà
How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing - Stock Traders Daily
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock new upside? - AD HOC NEWS
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock biotech upsi - AD HOC NEWS
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 29.26 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 29.26 USD - Investing.com
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $66 - Moomoo
IMVT Maintained by Goldman Sachs -- Price Target Raised to $32 - GuruFocus
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up - TipRanks
Immunovant (IMVT) CTO stout sells $251k in shares By Investing.com - Investing.com Canada
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com India
Insider Selling: Immunovant (NASDAQ:IMVT) Insider Sells 5,165 Shares of Stock - MarketBeat
Jay Stout Sells 10,132 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) CTO stout sells $251k in shares - Investing.com
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations - Stock Titan
(IMVT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan
Immunovant (IMVT) director receives RSU and stock option grants - Stock Titan
Immunovant (IMVT) grants director Douglas J. Hughes RSUs and stock options - Stock Titan
Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan
Immunovant (IMVT) awards RSUs and stock options to director Jake Bauer - Stock Titan
Immunovant (IMVT) director receives 13,880 RSUs and 7,061 options - Stock Titan
Immunovant (IMVT) COO receives new stock options and RSU grants - Stock Titan
Immunovant (IMVT) CTO granted 96,851 options and 66,937 RSUs - Stock Titan
Immunovant (IMVT) CLO receives 59,820 options and 41,343 RSUs - Stock Titan
Immunovant (IMVT) CEO awarded new stock options and RSUs in equity grant - Stock Titan
Immunovant (IMVT) CFO awarded RSUs and 94,002 options under 2019 plan - Stock Titan
Wolfe Research Maintains Immunovant(IMVT.US) With Buy Rating, Announces Target Price $47 - Moomoo
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $42 - Moomoo
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):